Ísrael - enska - Ministry of Health

neopharm scientific ltd - lenalidomide - hard capsule - lenalidomide 5 mg - lenalidomide - lenalidomide - multiple myeloma (mm) revlimid is indicated for the treatment of multiple myeloma.myelodysplastic syndromes revlimid is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.revlimid 7.5 mg is not indicated for treatment in mds.mantle cell lymphomarevlimid is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphomarevlimid in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Ísrael - enska - Ministry of Health

neopharm scientific ltd - lenalidomide - hard capsule - lenalidomide 5 mg - lenalidomide - lenalidomide - multiple myeloma (mm) revlimid is indicated for the treatment of multiple myeloma.myelodysplastic syndromes revlimid is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.revlimid 7.5 mg is not indicated for treatment in mds.mantle cell lymphomarevlimid is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphomarevlimid in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Ísrael - enska - Ministry of Health

neopharm scientific ltd - lenalidomide - hard capsule - lenalidomide 10 mg - lenalidomide - lenalidomide - multiple myeloma (mm) revlimid is indicated for the treatment of multiple myeloma.myelodysplastic syndromes revlimid is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.revlimid 7.5 mg is not indicated for treatment in mds.mantle cell lymphomarevlimid is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphomarevlimid in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Ísrael - enska - Ministry of Health

neopharm scientific ltd - lenalidomide - hard capsule - lenalidomide 10 mg - lenalidomide - lenalidomide - multiple myeloma (mm)revlimid is indicated for the treatment of multiple myeloma.myelodysplastic syndromes revlimid is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.revlimid 7.5 mg is not indicated for treatment in mds.mantle cell lymphomarevlimid is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphomarevlimid in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Ísrael - enska - Ministry of Health

neopharm scientific ltd - lenalidomide - hard capsule - lenalidomide 15 mg - lenalidomide - lenalidomide - multiple myeloma (mm)revlimid is indicated for the treatment of multiple myeloma.myelodysplastic syndromes revlimid is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.revlimid 7.5 mg is not indicated for treatment in mds.mantle cell lymphomarevlimid is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphomarevlimid in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Ísrael - enska - Ministry of Health

neopharm scientific ltd - lenalidomide - hard capsule - lenalidomide 15 mg - lenalidomide - lenalidomide - multiple myeloma (mm)revlimid is indicated for the treatment of multiple myeloma.myelodysplastic syndromes revlimid is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.revlimid 7.5 mg is not indicated for treatment in mds.mantle cell lymphomarevlimid is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphomarevlimid in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Ísrael - enska - Ministry of Health

neopharm scientific ltd - lenalidomide - hard capsule - lenalidomide 25 mg - lenalidomide - lenalidomide - multiple myeloma (mm)revlimid is indicated for the treatment of multiple myeloma.myelodysplastic syndromes revlimid is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.revlimid 7.5 mg is not indicated for treatment in mds.mantle cell lymphomarevlimid is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphomarevlimid in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Ísrael - enska - Ministry of Health

neopharm scientific ltd - lenalidomide - hard capsule - lenalidomide 25 mg - lenalidomide - lenalidomide - multiple myeloma (mm)revlimid is indicated for the treatment of multiple myeloma.myelodysplastic syndromes revlimid is indicated for patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (mds) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.revlimid 7.5 mg is not indicated for treatment in mds.mantle cell lymphomarevlimid is indicated for the treatment of adult patients with relapsed and/or refractory mantle cell lymphoma (mcl).follicular lymphomarevlimid in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma.

Ísrael - enska - Ministry of Health

rafa laboratories ltd - oxycodone hydrochloride - tablets controlled release - oxycodone hydrochloride 20 mg - oxycodone - oxycodone - for the relief of moderate severe chronic pain.

Ísrael - enska - Ministry of Health

rafa laboratories ltd - oxycodone hydrochloride - tablets controlled release - oxycodone hydrochloride 10 mg - oxycodone - oxycodone - for the relief of moderate to severe chronic pain.